-
Infosys Technologies And Elan Pharmaceuticals Apply Co-Creation Model To Transform Discovery Research
2/5/2010
Infosys Technologies Limited (Nasdaq:
INFY) today announced that it will design and implement the Research Informatics System (RISe) at Elan Pharmaceuticals, Inc (NYSE:
ELN), a leading biotechnology company, to accelerate discovery research using a path-breaking co-creation engagement model that leverages Infosys' existing intellectual property in this field.
-
GSK Launches New Specialist Unit To Research And Develop Medicines For Rare Diseases
2/5/2010
GSK recently announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases.
-
The Colorado Institute For Drug, Device And Diagnostic Development Launches With A Statewide 'Call For Proposals' From Life Science Technologies In Need Of Funding And Active Management
2/4/2010
The Colorado Institute for Drug, Device and Diagnostic Development (CID4) launches this month with a statewide "Call for Proposals" from Colorado life science technologies in need of funding and active management. The announcement is made by Kevin M. Smith, CID4 Executive Vice President/COO and spokesperson
-
Medical Research Council Technology's Centre For Therapeutics Discovery Opens Its First 'Call For Targets' In An Effort To Develop Drugs In Areas Of Serious Unmet Need
2/4/2010
A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today
-
Vantia Therapeutics’ Lead Candidate VA106483 Enters Phase IIb Trial For Nocturia
2/4/2010
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, recently announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia
-
Kantar Health And ImpactRx Launch CancerMPact Monthly Drugs And Regimens For Oncology Business Decisions
2/3/2010
Kantar Health, a leading healthcare-focused consultancy and oncology center of excellence, and
ImpactRx, a pioneer in tracking and evaluating pharmaceutical promotion on the prescribing behavior of physicians, announced their partnership to introduce CancerMPact Monthly Drugs and Regimens, a timely, robust tool to assess oncology drug and regimen utilization
-
Advanced Cancer Therapeutics Funds Brown Cancer Center Research Scientist to Accelerate Identification Of Clinical Candidates
2/3/2010
Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, recently announced that it has signed an agreement to leverage the computational chemistry expertise of Dr. John Trent, Associate Professor, Department of Medicine at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center), to accelerate the identification of new clinical candidates for the prevention and treatment of cancer. As part of this agreement, over the
-
Pall Corporation Introduces The PallSep Biotech Filtration System For Difficult-To-Process Biotechnology Feed Streams
2/2/2010
Pall Corporation, a global leader in filtration, separation and purification, has introduced the PallSep Biotech system for the gentle separation of target molecules from complex biotechnology process fluids.
-
Entelos Granted Patent For Innovative Diagnostic Capability In Obesity, Diabetes
2/2/2010
Entelos, Inc., a simulation and modeling companyfocused on human health, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,654,955 entitled "Apparatus and Methods for Assessing Metabolic Substrate Utilization" to the Company
-
FDA Accepts Javelin Pharmaceuticals’ Dyloject New Drug Application For Formal Review
2/2/2010
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, recently announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject (diclofenac sodium) Injection, has been accepted for formal review
